Comparative hemodynamic effect of metrizamide and Renografin 76 in infants with congenital heart disease.
Twenty patients under the age of 2 years with suspected congenital heart disease received alternately Renografin 76 and metrizamide for angiocardiography. The dose was 2.0 ml/kg per injection for both contrast media into the left ventricle. Metrizamide induced slightly lesser change in heart rate, peak systolic pressure, and peak end-diastolic pressures. Serum osmolality, hematocrit, and serum electrolytes were affected equally by the contrast media. Metrizamide was well tolerated by the neonates with congenital heart disease and its radiopacity was adequate for diagnostic purposes. At the doses administered, metrizamide does not seem to have any great advantage over Renografin 76 for angiocardiography in infants with severe congenital heart disease.
D000790:Angiocardiography; D001794:Blood Pressure / Q000187:drug effects; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003973:Diatrizoate / Q000031:analogs & derivatives* / Q000494:pharmacology*; D003974:Diatrizoate Meglumine / Q000494:pharmacology*; D004338:Drug Combinations / Q000494:pharmacology; D004573:Electrolytes / Q000097:blood; D005260:Female; D006330:Heart Defects, Congenital / Q000000981:diagnostic imaging*; D006339:Heart Rate / Q000187:drug effects; D006400:Hematocrit; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008793:Metrizamide / Q000494:pharmacology*; D009994:Osmolar Concentration; D013997:Time Factors
D004338:Drug Combinations; D004573:Electrolytes; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D008793:Metrizamide